Free tool
FAERS Monitor: Promethazine Hydrochloride and Dextromethorphan Hydrobromide
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 011265 or its brand name (Promethazine Hydrochloride and Dextromethorphan Hydrobromide, Dextromethorphan Hydrobromide, Promethazine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
3
Serious
2
67% of reports
Hospitalization
1
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- colectomy1
- intestinal obstruction1
- neuropathy peripheral1
- product use in unapproved indication1
- somnolence1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,156 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| colectomy | 1 | 1241.3 | 250.5 | 309 |
| intestinal obstruction | 1 | 186.0 | 37.5 | 46 |
| neuropathy peripheral | 1 | 73.7 | 14.9 | 18 |
| somnolence | 1 | 34.8 | 7.0 | 8 |
| product use in unapproved indication | 1 | 28.3 | 5.7 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.